This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 48/5/914    most recent 01.HYP.0000244543.91937.79v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rice, G. I. Articles by Hooper, N. M. Search for Related Content PubMed PubMed Citation Articles by Rice, G. I. Articles by Hooper, N. M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Related Collections ACE/Angiotension receptors Hypertension - basic studies Genetics of cardiovascular disease

(Hypertension. 2006;48:914.)
© 2006 American Heart Association, Inc.

Original Articles

Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family Study

Gillian I. Rice; Amy L. Jones; Peter J. Grant; Angela M. Carter; Anthony J. Turner; Nigel M. Hooper

From the Proteolysis Research Group (G.I.R., A.L.J., A.J.T., N.M.H.), Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, and Leeds Institute of Genetics Health and Therapeutics, (G.I.R., A.L.J., P.J.G., A.M.C.), University of Leeds, Leeds, United Kingdom.

Correspondence to Gillian I. Rice, Leeds Institute of Genetics, Health and Therapeutics, Light Laboratories, Clarendon Way, University of Leeds, Leeds, LS2 9JT United Kingdom. E-mail bmbgir{at}bmb.leeds.ac.uk

The renin–angiotensin system is a key regulator of blood pressure (BP), with inhibitors of angiotensin-converting enzyme (ACE) used clinically to treat hypertension and other cardiovascular conditions. ACE2 is a newly identified member of this system, which converts angiotensin II to angiotensin (1-7), and of which the occurrence in plasma has not been investigated. The aim of this study was to determine the heritability of circulating ACE, ACE2, and neprilysin (NEP), which may also be a regulator of BP, in a family study, and to determine covariates that contribute to the variation in plasma activity. ACE, ACE2, and NEP activities were measured in plasma from 534 subjects in the Leeds Family Study using selective fluorogenic substrates. Genetic factors accounted for 24.5%, 67%, and 22.7% of the phenotypic variation in circulating ACE, ACE2, and NEP, respectively. ACE insertion/deletion polymorphism and other measured covariates accounted for 23.8% of variance in circulating ACE. High-density lipoprotein cholesterol was a significant determinant of circulating ACE2. Measured covariates accounted for 17.3% of variation in circulating NEP. ACE and NEP were associated with systolic and diastolic BP in univariate analyses; however, only ACE was independently associated with systolic and diastolic BP after accounting for covariates and shared childhood household.

Key Words: angiotensin • blood pressure • genetics • metalloproteinases • population

This article has been cited by other articles:

				M. Iwata, J. E. Silva Enciso, and B. H. Greenberg Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor {alpha}-converting enzyme Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1318 - C1329. [Abstract] [Full Text] [PDF]

				Z. W. Lai, R. A. Lew, M. A. Yarski, F.-T. Mu, R. K. Andrews, and A. I. Smith The Identification of a Calmodulin-Binding Domain within the Cytoplasmic Tail of Angiotensin-Converting Enzyme-2 Endocrinology, May 1, 2009; 150(5): 2376 - 2381. [Abstract] [Full Text] [PDF]

				B. Rentzsch, M. Todiras, R. Iliescu, E. Popova, L. A. Campos, M. L. Oliveira, O. C. Baltatu, R. A. Santos, and M. Bader Transgenic Angiotensin-Converting Enzyme 2 Overexpression in Vessels of SHRSP Rats Reduces Blood Pressure and Improves Endothelial Function Hypertension, November 1, 2008; 52(5): 967 - 973. [Abstract] [Full Text] [PDF]

				S. Epelman, W.H. W. Tang, S. Y. Chen, F. Van Lente, G. S. Francis, and S. Sen Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System J. Am. Coll. Cardiol., August 26, 2008; 52(9): 750 - 754. [Abstract] [Full Text] [PDF]

				S. de Denus, M. Zakrzewski-Jakubiak, M.-P. Dube, F. Belanger, S. Lepage, M.-H. Leblanc, D. Gossard, A. Ducharme, N. Racine, L. Whittom, et al. Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan Ann. Pharmacother., July 1, 2008; 42(7): 925 - 932. [Abstract] [Full Text] [PDF]

				P.-a. B. Shih and D. T. O'Connor Hereditary Determinants of Human Hypertension: Strategies in the Setting of Genetic Complexity Hypertension, June 1, 2008; 51(6): 1456 - 1464. [Full Text] [PDF]

				R. A. Lew, F. J. Warner, I. Hanchapola, M. A. Yarski, J. Manohar, L. M. Burrell, and A. I. Smith Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor Exp Physiol, May 1, 2008; 93(5): 685 - 693. [Abstract] [Full Text] [PDF]

				K. M. Elased, T. S. Cunha, F. K. Marcondes, and M. Morris Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice Exp Physiol, May 1, 2008; 93(5): 665 - 675. [Abstract] [Full Text] [PDF]